Innate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Henry Wheeler - VP, IR and Communication Mondher Mahjoubi - CEO Sonia Quaratino - Chief Medical Officer Yannis Morel - EVP, BD and Product Portfolio Strategy Rabib Chaudhury - Leerink Partners Carly Kenselaar - Citi Arthur He - H.C. Wainwright Jingming Chen - Evercore ISI Thank you for standing by, and welcome to the Innate Pharma Third Quarter 2023 Financial Results and Business Update. Henry Wheeler On Slide 2, ...

Company Participants Ashiq Mubarack - Citi Jingming Chen - Evercore ISI Daina Graybosch - Leerink Partners I'd now like to welcome Henry Wheeler to begin the conference. Henry, over to you. On Slide 2, before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Mondher Mahjoubi I ...

INNATE PHARMA SA HALF-YEAR FINANCIAL REPORT JUNE 30, 2023 INNATE PHARMA S.A. French société anonyme governed by an Executive Board and a Supervisory Board with a share capital of 4,026,535.85 euros composed of 80,516,622 ordinary shares, and 14,095 preferred shares with a nominal value of 0.05 euros each Registered office: 117, Avenue de Luminy, F-13009 Marseille, France Registered with the Company and Trade Register of Marseille under number 424 365 336 The following interim condensed consolidated financia ...

Disclaimer on Forward-Looking Information and Risk Factors This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to i statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertairi cause the Company's actual results or financial condition to differ materially from those anticipated. Thes ...

Company Participants Ashiq Mubarack - Citigroup Daina Graybosch - SVB Securities Swayampakula Ramakanth - H.C. Wainwright & Co. Justine Telliez - Kepler Cheuvreux Jingming Chen - Evercore ISI Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release providing a business update for Q1 2023. We look forward to highlighting the progress made during the year todate as well as addressing future goals and milestones. The press release and today's presentation are ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of April 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0) 4 30 30 30 (Address of principal executive office) Indicate by check mark whether the registran ...

Europe Demonstrates better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models. | --- | --- | --- | --- | --- | --- | --- | --- | |------------------|----------------------|--------|-----------------------------------|----------------|-------|-----------------------|----------------| | | | | | | | | | | | IPH6101/SAR'579 | | IPH6401/SAR'514 | IPH62 | | OPTION | | | Ongoing programs | CD123 Phase 1 in AML | | Progression towards IND | B7-H3 Research | | 2 undisclosed targets | ...

Mondher Mahjoubi Operator Mondher Mahjoubi Mondher Mahjoubi Mondher Mahjoubi Mondher Mahjoubi Ladies and gentlemen, thank you for participating. This concludes today's conference call. You may now disconnect. Conference Call Participants Operator Innate Pharma S.A. (NASDAQ:IPHA) Q4 2022 Earnings Conference Call March 23, 2023 9:00 AM ET Henry Wheeler - Head, Investor Relations Mondher Mahjoubi - Chief Executive Officer Joyson Karakunnel - Executive Vice President and Chief Medical Officer Yannis Morel - Exe ...

Exhibit 99.1 Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET® program and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutaneous T cell lymphoma in Sézary syndrome and mycosis fungoides First patient dosed in monalizumab PACIFIC-9 Phase 3 lung cancer clinical trial with $50M payment from AstraZeneca Cash p ...